# A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

> **NCT05606614** · PHASE3 · RECRUITING · sponsor: **Taysha Gene Therapies, Inc.** · enrollment: 15 (estimated)

## Conditions studied

- Rett Syndrome

## Interventions

- **GENETIC:** TSHA-102

## Key facts

- **NCT ID:** NCT05606614
- **Lead sponsor:** Taysha Gene Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2031-06
- **Final completion:** 2031-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05606614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05606614, "A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05606614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*